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PCN10
COST OF HOSPITALIZATION FOR THORACIC 
SURGERY IN PATIENTS WITH LUNG CANCER
IN GREECE
Leftakis A1, Geitona M2
1Thoracic Diseases SOTIRIA Hospital, Athens, Greece; 
2National School of Public Health, Athens, Greece
OBJECTIVES: To estimate the cost of hospitalization for
thoracic surgery in patients with lung cancer, admitted to
the Intensive Care Unit (ICU) of “SOTIRIA” General
District Hospital in Athens.
METHODS: The chosen ICU is part of one of the largest
specialized thoracic disease hospitals in Greece. Methodol-
ogy is based on a retrospective study of patient records
over a six-month period from September 1st 1997 to Feb-
ruary 28th 1998. The sample consisted of 95 patients.
Clinical data were derived from patients’ medical records,
while administrative, economic and other data came from
the Hospital’s administrative/financial department. Cost
analysis is based on the cost of personnel, supplies, medi-
cation, laboratory and imaging tests, cost of infrastructure,
hotel services and various on-site costs. Descriptive statisti-
cal analysis and frequencies were determined for the age,
gender, hospital and length of stay (LOS-pre and postoper-
ative inpatient stay) in ICU, severity of illness, resource
consumption and ICU outcome (survival or death). All
costs are reported in 1998 US dollars.
RESULTS: 218 patients from the five “SOTIRIA” hospi-
tal surgical departments were admitted to the ICU, 95 of
whom (43.6%) were patients who underwent surgery for
lung cancer. They had a total of 2,011 inpatient days and
276 inpatient days in the ICU. LOS in the hospital was
21.1 days and 2.9 days in the ICU. LOS for the preopera-
tive period was 7.9 days and 10.3 days postoperative.
Total patient-hospitalization costs in the ICU are esti-
mated at US$ 191,065 (pre) and US$ 2,011(post) per pa-
tient. Major cost components are salaries of personnel
(41.7%), diagnostic tests (23%), and medication (15%).
Mean hospitalization cost for a thoracic surgery patient
with lung cancer is estimated at US$ 6,958.
CONCLUSIONS: Economic analysis could substantially
contribute to the costing of diseases and would enable
Greek policy makers to obtain the information required
for their decision-making.
PCN11
COST-EFFECTIVENESS OF SENTINEL LYMPH 
NODE MAPPING AND ADJUVANT INTERFERON 
THERAPY FOR STAGE II MELANOMA
Wilson LS, Reyes CM, Lu C, Lu M, Yen C
University of California San Francisco, San Francisco, CA, USA
OBJECTIVE: Clinical studies have demonstrated that
high dose adjuvant interferon therapy improves disease-
free and overall survival among high-risk (stage IIb and
stage III) melanoma patients. Sentinel lymph node map-
ping (SLM) identifies metastasis and more accurately dif-
ferentiates between stage II patients at high risk, who
then might benefit most from adjuvant interferon ther-
apy. We analyzed the cost-effectiveness of first testing
with sentinel lymph node mapping (SLM) and then treat-
ing with adjuvant interferon (IFN) therapy for stage II
melanoma.
METHODS: We used a decision analytic model to com-
pare four strategies for stage II patients after surgical ex-
cision of their melanoma: 1) treat all with low dose IFN;
2) test first with SLM and then treat only those with pos-
itive micrometastases with high dose IFN; 3) test first
with SLM and treat positives with high dose and nega-
tives with low dose IFN (test and treat appropriately); 4)
treat no one. Treatment, toxicity, follow-up and relapse
costs were included. The primary outcome was cost per
quality adjusted life year (QALY)
RESULTS: Our analyses show that it is cost-effective to
first test with SLM and treat appropriately compared to
treating all with low dose IFN ($12,400/QALY). More-
over, it is cost-effective to test and treat appropriately
versus testing and only treating some with high dose
($27,100/QALY). It is also more cost-effective to test and
treat appropriately compared to no treatment ($31,700/
QALY).
CONCLUSION: Appropriate dosing of IFN therapy
based on the results of sentinel lymph node mapping is a
cost-effective strategy for stage II melanoma patients.
PCN12
THE RELATIONSHIP OF AGE AND DURATION 
OF HORMONAL THERAPY USE AMONG 
PATIENTS DIAGNOSED WITH CANCER
OF THE PROSTATE
Stolshek B1, Hersom K2, Pelletier E2, Delgado D1
1Amgen, Inc, Thousand Oaks, CA; 2 The Lewin Group, San 
Francisco, CA
OBJECTIVE: The utilization of LHRH agonists and anti-
androgens in prostate cancer has resulted from both their
availability and the substantial regret of patients follow-
ing orchiectomy. Previously unavailable, this study de-
scribes hormonal therapy resource use by age group and
duration from a large payer claims database.
METHODS: Male patients were identified in the Synergy
data warehouse from 03/1999 to 07/2000 with age 40,
a claim for prostate cancer specific LHRH agonist medi-
cation, any additional prescription claim, and continuous
medical and pharmacy enrollment. New cases of LHRH
agonist monotherapy (MONO) or combination therapy
with anti-androgen (CAB) were defined as no MONO or
CAB during the 4 months prior to 3/1999. Therapy
groups were stratified by age group (65 (younger) and
65 (older)) and followed until 07/2000. Descriptive sta-
tistics were used to summarize the data.
RESULTS: 582 younger patients and 878 older patients
were identified. 93.0% of the younger patients had pri-
vate insurance compared to 28.2% government and
71.8% private insurance in the older patients. Average
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duration of all LHRH agonist use was 26.3 weeks and 33.2
weeks in younger and older patients, respectively (P  0.05).
LHRH agonists were used for 24 weeks and 48 weeks in
56.4% and 17.6% of younger and in 43.3% and 28.3% of
older patients. Average duration of anti-androgen use for
CAB patients was 34.7 and 39.8 weeks in younger (n  80)
and older patients (n  117, P  ns). Anti-androgens were
used for 24 weeks and 48 weeks in 43.8% and 31.3% of
younger and in 40.2% and 36.8% of older patients.
CONCLUSIONS: The duration of LHRH agonist use by
prostate cancer patients varies by age. Large proportions
of patients in both age groups use CAB for 24 weeks,
suggesting use to protect against testosterone surge. Ad-
ditional research is required to verify these results.
PCN13
PHARMACOECONOMIC ANALYSIS OF 
ADVANCED NON-SMALL CELL LUNG CANCER 
TREATMENT WITH DOCETAXEL-CISPLATIN, 
PACLITAXEL-CISPLATIN AND 
PACLITAXEL-CARBOPLATIN
Rubio Terrés C1, Tisaire JL1, Kobina S2, Moyano A3
1Aventis Pharma, S.A, Madrid, Spain; 2Aventis Pharma, 
Bridgewater, NJ, USA; 3Hospital Ramón y Cajal, Madrid, Spain
OBJECTIVES: To compare the efficiency (the evaluation
of efficacy in relation to costs) of three first-line treatment
options for advanced non-small-cell lung cancer (stage IIIB
and IV) used in the ECOG study: docetaxel/cisplatin (75/
75 mg/m2/day; 1 hour IV infusion of docetaxel); paclitaxel/
cisplatin (175/75 mg/m2/day; 3 or 24 hour IV infusion of
paclitaxel), and paclitaxel/carboplatin (175/400 or 225/
400 mg/m2/day; 3 hour IV infusion of paclitaxel).
METHODS: The results of the ECOG 1594 phase III clin-
ical trial demonstrated equivalent efficacy (survival, objec-
tive response) between the treatment options. To differen-
tiate between the treatment options, we performed a cost-
minimization analysis, using a pharmacoeconomic model.
RESULTS: The average estimated treatment cost per patient
(median, four cycles) with docetaxel/cisplatin would be
1,067,836 Spanish pesetas (Ptas) (€6481; 5741 USD),
1,365,304 or 1,439,369 Ptas (€8205 or €8651; 7340 or
7738 USD) with paclitaxel/cisplatin (3 or 24 hour infusions,
respectively), and 1,417,995 or 1,616,784 Ptas (€8522 or
€9717; 7623 or 8692 USD) (paclitaxel dose of 175 or 225
mg/m2/day, respectively) with paclitaxel/carboplatin.
CONCLUSIONS: According to our study, the treatment
option docetaxel/cisplatin, with equal efficacy, would re-
sult in a cost saving of between 297,468 and 548,948
Ptas (1788 and 3299 € or 1599 and 2951 USD) per pa-
tient treated. This difference is mainly due to the lower
treatment cost associated with docetaxel.
PCN14
CHEMOTHERAPY-INDUCED NEUROPATHY IN 
OVARIAN CANCER COST 
EFFECTIVENESS ANALYSIS
Hay JW, Patel BV
University of Southern California, Los Angeles, CA, USA
OBJECTIVE: Many widely used chemotherapy agents,
including paclitaxel and cisplatin produce neuropathy in
cancer patients. These symptoms are dose-related, some-
times irreversible, and can lead to treatment withdrawal.
To evaluate reported chemotherapy cost-effectiveness, we
assessed the literature on cost and quality of life burden
of chemotherapy-induced neuropathy in ovarian cancer
(OC) patients.
METHODS: MEDLINE was searched for all articles
published in English between 1966 and June 2001 match-
ing neuropathy or cancer with keywords: quality of life;
burden of disease; cost; cost-effectiveness; cost of illness;
indirect cost. Findings from all relevant international stud-
ies were combined to assess neuropathy cost and utility
burden.
RESULTS: Eight hundred eighty four relevant study refer-
ences were identified and reviewed. Only two studies sys-
tematically evaluated the utility loss associated with severe
neuropathy, and only one study reported indirect cost bur-
den of OC neuropathy. No single analysis provided a com-
prehensive assessment of chemotherapy-induced neuropathy
on treatment cost-effectiveness. Clinical evidence suggests
that the burden is substantial. Up to 57% of cisplatin pa-
tients, and 62% of paclitaxel patients experienced significant
neuropathy symptoms. Quality of life decreased by 17–24%
for OC patients experiencing severe neuropathy. Using 2001
US prices and including the indirect costs and quality of life
impacts, the effect of severe neuropathy would be to increase
typically reported base case cost-effectiveness of pacli-
taxel in OC treatment from $33,300/QALY to $52,800/
QALY. Similar results were found for other oncology medi-
cations.
CONCLUSIONS: Neuropathy quality of life and cost
burden has been ignored in the chemotherapy cost-effec-
tiveness literature, because direct treatment costs are
small and quality of life impacts due to neuropathy in
OC patients are rarely explicitly measured. Nevertheless,
this treatment toxicity may have a substantial effect on
chemotherapy cost-effectiveness, possibly increasing re-
ported medication cost/QALY estimates by 60%. More
research is needed to quantify the cost and quality of life
burdens of chemotherapy-induced neuropathy.
PCN15
QOL CHANGE OVER TIME POST-REINFUSION 
OF PBPC IN HIGH DOSE TREATMENT OF NON-
HODGKIN’S FOLLICULAR LYMPHOMA (N-HFL) 
WITH AND WITHOUT FILGRASTIM USE
Van Kriekinge G1, Coiffier B2, Witz B3, Erder HM4, Standaert B1
1Amgen Inc, Brussels, Belgium; 2Centre Hospitalier Lyon Sud, 
Pierre Bénite, France; 3Hôpital Brabois, Vandoeuvre les Nancy, 
France; 4Amgen Inc, Thousand Oaks, CA, USA
OBJECTIVES: To assesses the quality of life (QoL) with
Q-TwiST retrospectively in a randomised phase III trial
